MicroRNA (miR)-124: A Promising Therapeutic Gateway for Oncology

Gourishetti, Karthik; Balaji Easwaran, Vignesh; Mostakim, Youssef; Ranganath Pai, K. Sreedhara; Bhere, Deepak

doi:10.3390/biology12070922

Cited by 2 publications

(1 citation statement)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, guaranteeing the safety and effectiveness of these new therapies is necessary. Additionally, combining these therapies with conventional chemotherapy could facilitate treatment development, increase patient survival rates and prevent or cure refractory or relapsed ALL [ 107 , 108 ].…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

The Role of miRNAs in Childhood Acute Lymphoblastic Leukemia Relapse and the Associated Molecular Mechanisms

Barrios-Palacios,

Organista-Nava,

Balandrán

et al. 2023

IJMS

View full text Add to dashboard Cite

Acute lymphoblastic leukemia (ALL) is the most common cancer in children worldwide. Although ALL patients’ overall survival rates in wealthy countries currently surpass 80%, 15–20% of patients still experience relapse. The underlying mechanisms of relapse are still not fully understood, and little progress has been made in treating refractory or relapsed disease. Disease relapse and treatment failure are common causes of leukemia-related death. In ALL relapse, several gene signatures have been identified, but it is also important to study miRNAs involved in ALL relapse in an effort to avoid relapse and to achieve better survival rates since miRNAs regulate target genes that participate in signaling pathways involved in relapse, such as those related to drug resistance, survival signals, and antiapoptotic mechanisms. Several miRNAs, such as miR-24, miR-27a, miR-99/100, miR-124, miR-1225b, miR-128b, miR-142-3p, miR-155 and miR-335-3p, are valuable biomarkers for prognosis and treatment response in ALL patients. Thus, this review aimed to analyze the primary miRNAs involved in pediatric ALL relapse and explore the underlying molecular mechanisms in an effort to identify miRNAs that may be potential candidates for anti-ALL therapy soon.

show abstract

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%